PBLS Stock Summary and Trading Ideas (Parabilis Medicines | NASDAQ:PBLS)

Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between ß-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/ß-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.

Parabilis Medicines trades on the NASDAQ stock market under the symbol PBLS.

As of September 8, 2026, PBLS stock price declined to $39.77 with 531,188 million shares trading.

PBLS has a beta of -0.63, meaning it tends to be less sensitive to market movements. PBLS has a correlation of 0.05 to the broad based SPY ETF.

PBLS has a market cap of $4.91 billion. This is considered a Mid Cap stock.

Last quarter Parabilis Medicines reported $148,000 in Revenue and -$2.32 earnings per share. This fell short of revenue expectation by $-17 million and missed earnings estimates by -$2.09.

The top ETF exchange traded funds that PBLS belongs to (by Net Assets): VTI, VB, VBR, VBK, ONEQ.

PBLS support price is $39.00 and resistance is $41.84 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PBLS shares will trade within this expected range on the day.